Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Reduced-Intensity Conditioning with FBA/FBAA Regimen Is Feasible for Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML): Interim Results of a Multicenter Clinical Trial in China.

Jianmin Wang, M.D., Jiong Hu, M.D., Chun Wang, M.D., Xinghua Chen, M.D., Jian Hou, M.D., Weiping Zhang, M.D., Wei Tang, M.D., Shike Yan, M.D., Xi Zhang, M.D., Lili Zhou, M.D., Jun Hou, M.D.

Blood (2009) 114 (22): 196.

https://doi.org/10.1182/blood.V114.22.196.196

Published: 2009

Journal Articles

Comparison of 12-Month Treatment Costs for Patients with Advanced Phase Chronic Myeloid Leukemia (CML) in China: Imatinib (IM) vs. Chemotherapy (Chemo) Plus Interferon-(IFN) in Accelerated Phase (AP) CML and IM vs. Chemo in Blast Crisis (BC) CML.

Zi Chen, M.D., Ph.D., Chun Wang, M.D., Weiwei Feng, PhD

Blood (2007) 110 (11): 5169.

https://doi.org/10.1182/blood.V110.11.5169.5169

Published: 2007

Journal Articles

Imatinib Is Cost-Effective Comparing to Interferon-(IFN) for Patients with Newly Diagnosed Chronic-Phase (CP) Chronic Myeloid Leukemia (CML) from the Chinese Public Healthcare System Perspective.

Chun Wang, M.D., Zi Chen, M.D., Ph.D., Weiwei Feng, PhD

Blood (2007) 110 (11): 5170.

https://doi.org/10.1182/blood.V110.11.5170.5170

Published: 2007

Journal Articles

Imatinib Versus Interferon-alpha (IFN) for Patients with Newly Diagnosed Chronic-Phase (CP) Chronic Myeloid Leukemia (CML) from the Chinese Public Healthcare System Perspective: 12 Months Cost and Cost Per Responder Analyses.

Chun Wang, M.D., Zi Chen, M.D., Ph.D., Weiwei Feng, PhD

Blood (2007) 110 (11): 5171.

https://doi.org/10.1182/blood.V110.11.5171.5171

Published: 2007

Journal Articles

High Efficacy and Good Tolerability with Rituximab In Vivo Purging Followed by High Dose Chemotheraphy and Autologous Peripheral Blood Stem Cell Transplantation (APBSCT) in Non-Hodgkin’s Lymphoma (NHL).

Yuankai Shi, M.D., Sheng Yang, M.D., Xiaohong Han, M.D., Peng Liu, M.D., Xiaohui He, M.D., Jun Ma, M.D., Hanyun Ren, M.D., Xi’nan Cen, M.D., Shuyuan Zhou, M.D., Chun Wang, M.D.

Blood (2004) 104 (11): 4626.

https://doi.org/10.1182/blood.V104.11.4626.4626

Published: 2004

NARROW

Reduced-Intensity Conditioning with FBA/FBAA Regimen Is Feasible for Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML): Interim Results of a Multicenter Clinical Trial in China.

Comparison of 12-Month Treatment Costs for Patients with Advanced Phase Chronic Myeloid Leukemia (CML) in China: Imatinib (IM) vs. Chemotherapy (Chemo) Plus Interferon-(IFN) in Accelerated Phase (AP) CML and IM vs. Chemo in Blast Crisis (BC) CML.

Imatinib Is Cost-Effective Comparing to Interferon-(IFN) for Patients with Newly Diagnosed Chronic-Phase (CP) Chronic Myeloid Leukemia (CML) from the Chinese Public Healthcare System Perspective.

Imatinib Versus Interferon-alpha (IFN) for Patients with Newly Diagnosed Chronic-Phase (CP) Chronic Myeloid Leukemia (CML) from the Chinese Public Healthcare System Perspective: 12 Months Cost and Cost Per Responder Analyses.

High Efficacy and Good Tolerability with Rituximab In Vivo Purging Followed by High Dose Chemotheraphy and Autologous Peripheral Blood Stem Cell Transplantation (APBSCT) in Non-Hodgkin’s Lymphoma (NHL).

Email alerts

ASH Publications

American Society of Hematology

Reduced-Intensity Conditioning with FBA/FBAA Regimen Is Feasible for Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML): Interim Results of a Multicenter Clinical Trial in China.

Comparison of 12-Month Treatment Costs for Patients with Advanced Phase Chronic Myeloid Leukemia (CML) in China: Imatinib (IM) vs. Chemotherapy (Chemo) Plus Interferon-(IFN) in Accelerated Phase (AP) CML and IM vs. Chemo in Blast Crisis (BC) CML.

Imatinib Is Cost-Effective Comparing to Interferon-(IFN) for Patients with Newly Diagnosed Chronic-Phase (CP) Chronic Myeloid Leukemia (CML) from the Chinese Public Healthcare System Perspective.

Imatinib Versus Interferon-alpha (IFN) for Patients with Newly Diagnosed Chronic-Phase (CP) Chronic Myeloid Leukemia (CML) from the Chinese Public Healthcare System Perspective: 12 Months Cost and Cost Per Responder Analyses.

High Efficacy and Good Tolerability with Rituximab In Vivo Purging Followed by High Dose Chemotheraphy and Autologous Peripheral Blood Stem Cell Transplantation (APBSCT) in Non-Hodgkin’s Lymphoma (NHL).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only